tRNA Synthesis Service
Transfer RNA (tRNA) serves as the essential bridge between the genetic code and protein synthesis, acting as a molecular "translator" that delivers specific amino acids to the ribosome. At CD BioGlyco, we recognize that as the field of therapeutic nucleic acid development evolves, the demand for high-quality, precision-engineered tRNA has reached unprecedented levels. Our tRNA synthesis service is designed to provide researchers and pharmaceutical developers with the structural accuracy and chemical fidelity required for advanced applications such as nonsense mutation suppression and genetic code expansion (GCE).
Key Technologies
Enzymatic Tailor-Made Synthesis
We utilize high-fidelity T7 RNA polymerase systems and template-independent enzymatic methods to produce long-chain tRNA molecules with superior sequence accuracy.
Site-Specific Modification Chemistry
Our platform excels in the incorporation of post-transcriptional modifications such as pseudouridine (ψ), 2'-O-methylation, and thiolation, which are critical for tRNA stability and orthogonal recognition.
Advanced Purification and Folding
We employ multi-modal chromatography and specialized annealing protocols to ensure that every tRNA molecule adopts its correct cloverleaf 2-D and "L-shaped" 3-D conformation.
Unlocking the Potential of the Translation Machinery with Tailored tRNA Solutions
As a core component of our therapeutic nucleic acid development platform, CD BioGlyco provides a comprehensive tRNA synthesis service that addresses the diverse needs of the global research community. Our capabilities extend across the entire spectrum of tRNA biology:
- Custom Suppressor tRNA Synthesis: We design and synthesize specialized suppressor tRNAs (e.g., amber, ochre, and opal suppressors) capable of reading through premature termination codons (PTCs) to restore full-length protein function in genetic diseases.
- Orthogonal tRNA-Synthetase Pair Development: We provide synthesis for orthogonal tRNAs that do not cross-react with endogenous host machinery, facilitating the incorporation of non-canonical amino acids (ncAAs) for synthetic biology.
- Modified tRNA Variants: Our service includes the synthesis of tRNAs featuring rare or complex modifications that mimic endogenous molecules, enhancing their half-life and reducing immunogenicity for in vivo applications.
- tRNA-Derived Fragments (tRFs): We synthesize bioactive tRNA fragments to support research into their emerging roles as signaling molecules and diagnostic biomarkers.
Workflow
Project Consultation and Design
We begin with a detailed review of your target sequence, focusing on codon-anticodon pairing, structural integrity, and the necessity of specific nucleoside modifications.
Template Preparation and Synthesis
Using either high-purity DNA templates or solid-phase chemical strategies, we initiate the synthesis process. For longer sequences, we utilize enzymatic ligation of shorter fragments to maintain absolute sequence fidelity.
Systematic Modification Incorporation
During or post-synthesis, we incorporate functional groups and chemical modifications. This step is crucial for creating tRNAs that evade the innate immune system while maintaining high translation efficiency.
High-Resolution Purification
The raw synthesis product undergoes rigorous purification using high-performance liquid chromatography (HPLC) or polyacrylamide gel electrophoresis (PAGE) to remove truncated sequences and synthesis byproducts.
Structural Folding and Quality Control
The purified tRNA is annealed in specialized buffers to ensure correct secondary and tertiary folding. We perform mass spectrometry (MS) and capillary electrophoresis to confirm molecular weight and purity.
Bioactivity Validation
Optional aminoacylation assays are conducted to ensure the synthesized tRNA is a viable substrate for its cognate aminoacyl-tRNA synthetase (aaRS).
Publication Data
DoI: 10.1038/s41467-025-61671-8
Journal: Nature Communications
IF: 15.7
Published: 2025
Results: This study advances synthetic cell development by achieving continuous in situ synthesis of a complete set of 21 tRNAs to sustain steady-state translation in the PURE cell-free system. Researchers optimized tRNA transcription yields via promoter selection (T7 ϕ6.5 for most, ϕ2.5 for A-initiated tRNAs) and sequence mutations, eliminating 5′-processing needs. They demonstrated functional protein synthesis (sfGFP) using these in vitro transcription (IVT) tRNAs, with yield improvements by matching E. coli tRNA abundance.. In situ tRNA synthesis was enabled via 21 linear DNA templates or a single nicked plasmid (using Nt.BspQI) and post-transcriptional processing with T. maritima tRNase Z. Critically, on microfluidic chemostats, continuous in situ tRNA synthesis (from linear templates or nicked plasmids) supported steady-state protein expression for 20 h, overcoming resource competition by optimizing sfGFP template concentration. This work lays a key foundation for self-regenerating biochemical systems.
Fig.1 Preparation of IVT tRNAs, and consequent protein synthesis using IVT recombinant tRNAs or in situ synthesized tRNAs. (Li, et al., 2025)
Applications
Rare Disease Therapeutics
Developing treatments for Duchenne muscular dystrophy (DMD) and cystic fibrosis by suppressing nonsense mutations.
Synthetic Biology
Expanding the genetic code to create proteins with novel chemical properties for industrial and medical use.
Oncology Research
Investigating how altered tRNA profiles and modifications drive cancer progression and metastasis.
Protein Engineering
Site-specifically labeling proteins with fluorescent or reactive tags for structural studies and drug discovery.
Advantages
Unrivaled Expertise
Years of experience in glycobiology and nucleic acid chemistry ensure the successful synthesis of the most complex tRNA structures.
High Modification Fidelity
Ability to incorporate a vast library of epitranscriptomic marks with site-specific precision.
Scalability
From microgram quantities for pilot studies to milligram scales for preclinical in vivo testing.
Rigorous Quality Assurance
Every batch is accompanied by comprehensive analytical reports, including MS and HPLC data.
Frequently Asked Questions
Customer Review
"The team at CD BioGlyco provided exceptional support for our project involving amber suppressor tRNAs. The synthesis was fast, and the incorporation of specific 2'-fluoro modifications was flawless. Their technical insight significantly improved our in vitro suppression yields."
– A.S., Senior Researcher
"We were struggling with the stability of our engineered tRNA molecules until we switched to CD BioGlyco. Their expertise in structural folding and purification made a noticeable difference in our in vivo studies. A truly reliable partner for therapeutic nucleic acid research."
– B.R., Lead Scientist
"High-quality results and transparent communication. The analytical data provided with our custom tRNA order was comprehensive, allowing us to move forward with our genetic code expansion experiments with complete confidence."
– D.S., Professor of Synthetic Biology
Associated Services
CD BioGlyco is dedicated to advancing the frontiers of medicine through precision tRNA synthesis service. Our commitment to quality, combined with our advanced synthesis platform, makes us the ideal partner for your next breakthrough. Please feel free to contact us today to discuss your project requirements and receive a personalized quote.
Reference
- Li, F.; et al. Continuous in situ synthesis of a complete set of tRNAs sustains steady-state translation in a recombinant cell-free system. Nature Communications. 2025, 16: 6212. (Open Access)